

CITATION REPORT

List of articles citing

Phosphodiesterase inhibitors in airways disease

DOI: 10.1016/j.ejphar.2005.12.059

European Journal of Pharmacology, 2006, 533, 110-7.

Source: <https://exaly.com/paper-pdf/40759273/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
200	Corticosteroid insensitivity in smokers with asthma : clinical evidence, mechanisms, and management. 2006 , 5, 467-81		17
199	Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 1105-13	5.9	21
198	Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma. 2006 , 79, 2077-85		26
197	Novel molecular therapy. 2006 , 7 Suppl 1, S104-5		0
196	Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. 2006 , 36, 1494-504		73
195	Targeting signal transduction as a strategy to treat inflammatory diseases. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 549-63	64.1	228
194	Should treatments for asthma be aimed at the airway smooth muscle?. 2007 , 1, 209-17		10
193	cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. 2007 , 100, 950-66		247
192	Phosphodiesterases regulate airway smooth muscle function in health and disease. 2007 , 79, 61-74		13
191	cAMP signaling in leukocyte transendothelial migration. 2007 , 27, 1014-22		67
190	Summing up 100 years of asthma. 2007 , 101, 378-88		47
189	Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. 2007 , 418, 165-9		46
188	Novel medications for asthma: a look at the future. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 889-97	5.9	5
187	New molecular targets for the treatment of neutrophilic diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2007 , 119, 1055-62; quiz 1063-4	11.5	156
186	Biochemical aspects of inflammation. 2007 , 72, 595-607		29
185	Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. <i>European Journal of Pharmacology</i> , 2007 , 571, 215-21	5.3	34
184	Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3)H]-rolipram binding in guinea pig tissues. 2008 , 26, 417-24		23

183	Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. 2008 , 378, 149-69		42
182	Psychological factors in asthma. 2008 , 4, 12-28		38
181	Differential distribution of PDE4B splice variant mRNAs in rat brain and the effects of systemic administration of LPS in their expression. 2008 , 62, 74-9		27
180	Stereoelectronic properties of spiroquinazolinones in differential PDE7 inhibitory activity. 2008 , 29, 1945-54		25
179	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. <i>European Journal of Medicinal Chemistry</i> , 2008 , 43, 1349-59	6.8	29
178	Acetamide-45 inhibited hyperresponsiveness and airway inflammation in mice partly depending on phosphodiesterase activity suppression. 2008 , 29, 1195-201		1
177	PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. 2008 , 125-66		34
176	Airway epithelial cells –therapeutic targets for the treatment of COPD. 2008 , 5, 111-117		
175	pH Dependence of a 310-Helix versus a Turn in the M-Loop Region of PDE4: Observations on PDB Entries and an Electronic Structure Study. 2008 , 4, 974-84		2
174	A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells. 2008 , 8, 1408-17		15
173	Using guinea pigs in studies relevant to asthma and COPD. 2008 , 21, 702-20		72
172	Development and characterisation of a novel and rapid lung eosinophil influx model in the rat. 2008 , 21, 648-56		9
171	Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. 2008 , 21, 845-54		34
170	New targets for drug development in asthma. 2008 , 372, 1073-87		189
169	p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008 , 324, 921-9	4.7	87
168	Roflumilast: systemic therapy for chronic obstructive pulmonary disease. 2008 , 2, 539-49		6
167	Future therapies for chronic obstructive pulmonary disease. 2008 , 4, 66-70		1
166	Emerging pharmacotherapies for COPD. 2008 , 134, 1278-1286		89

165	Single-dose pharmacokinetics of roflumilast in children and adolescents. 2008 , 48, 978-85		8
164	New insights into airway remodelling in asthma and its possible modulation. 2008 , 8, 367-75		27
163	Genomic Aspects of Chronic Obstructive Pulmonary Disease. 2009 , 1098-1109		
162	Exacerbation rate, health status and mortality in COPD--a review of potential interventions. <i>International Journal of COPD</i> , 2009 , 4, 203-23	3	126
161	Functional antagonism of IL-1alpha induced gene expression profiles define the cAMP/PKA pathway as a unique regulator of IL-1alpha signaling networks. 2009 , 29, 246-56		1
160	Emerging drugs in chronic obstructive pulmonary disease. 2009 , 14, 181-94		6
159	Is there a role for antiinflammatory treatment in COPD?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 395-403	2	3
158	NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects. <i>European Journal of Pharmacology</i> , 2009 , 618, 63-9	5.3	6
157	Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. 2009 , 4, 866-76		53
156	Copy number gain at 8q12.1-q22.1 is associated with a malignant tumor phenotype in salivary gland myoepitheliomas. 2009 , 48, 202-12		11
155	Inhibition of HA synthase 3 mRNA expression, with a phosphodiesterase 3 inhibitor, blocks lung injury in a septic ventilated rat model. 2009 , 187, 233-9		11
154	Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. 2009 , 103, 342-7		14
153	Nebulized phosphodiesterase III inhibitor during warm ischemia attenuates pulmonary ischemia-reperfusion injury. 2009 , 28, 79-84		16
152	A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. 2009 , 10, 39		40
151	Immunomodulators. 2009 , 689-698		
150	A review of candidate pathways underlying the association between asthma and major depressive disorder. 2009 , 71, 187-95		70
149	Nicotine enhances murine airway contractile responses to kinin receptor agonists via activation of JNK- and PDE4-related intracellular pathways. 2010 , 11, 13		23
148	Ayanin, a non-selective phosphodiesterase 1-4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without affecting xylazine/ketamine-induced anesthesia. <i>European Journal of Pharmacology</i> , 2010 , 635, 198-203	5.3	4

147	Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration. <i>European Journal of Pharmacology</i> , 2010 , 643, 274-81	5.3	22
146	Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: Synthesis and evaluation of their phosphodiesterase 4 inhibitory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 3506-17	3.4	12
145	Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. <i>British Journal of Pharmacology</i> , 2010 , 159, 842-55	8.6	263
144	Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways. 2010 , 24, 73-82		2
143	Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. 2010 , 21, 1097-110		55
142	Evaluation of the effect of phosphodiesterase on equine platelet activation and the effect of antigen challenge on platelet phosphodiesterase activity in horses with recurrent airway obstruction. 2010 , 71, 534-40		7
141	Management of acute asthma in adults in the emergency department: nonventilatory management. 2010 , 182, E55-67		69
140	Pharmacologie. 2010 , 2, 54-64		
139	Vinpocetine as a potent antiinflammatory agent. 2010 , 107, 9921-2		51
138	Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. 2010 , 62, 726-59		516
137	The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. 2010 , 40, 36-42		69
136	New therapies for asthma: is there any progress?. 2010 , 31, 335-43		161
135	Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary disease. 2010 , 24, 1192-204		15
134	Targeting cancer with phosphodiesterase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 117-31	5.9	105
133	Asthma. 2011 , 95, 1115-24		4
132	The increase in rat ventricular automaticity induced by salbutamol is mediated through $\alpha(1)$ - but not $\alpha(2)$ -adrenoceptors: role of phosphodiesterases. 2011 , 88, 1095-101		5
131	Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension. 2011 , 251-77		28
130	Therapeutic approaches for tumor necrosis factor inhibition. 2011 , 47, 427-446		10

129	Synergic bronchodilator effects of a phosphodiesterase 3 inhibitor olprinone with a volatile anaesthetic sevoflurane in ovalbumin-sensitised guinea pigs. 2011 , 28, 519-24		3
128	Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 5451-6	2.9	20
127	New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 6567-72	2.9	8
126	Anthranilic acid-based inhibitors of phosphodiesterase: design, synthesis, and bioactive evaluation. <i>Organic and Biomolecular Chemistry</i> , 2011 , 9, 7113-25	3.9	11
125	Study on airway smooth muscle tone using fiberoptic bronchoscopy: basic research and clinical application. 2011 , 25, 147-51		
124	Hesperetin-7,3RO-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio. 2011 , 18, 84		15
123	Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 3307-12	2.9	21
122	Light-dark oscillations in the lung transcriptome: implications for lung homeostasis, repair, metabolism, disease, and drug action. 2011 , 110, 1732-47		51
121	Anti-Inflammatory Drugs in the Treatment of Meconium Aspiration Syndrome. 2011 , 11, 15-23		1
120	Development of new drugs for the treatment of respiratory diseases: from concept to the clinic. 2011 , 21, 347-352		2
119	Biochanin a, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness. 2011 , 2011, 635058		25
118	NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011 , 301, L441-50	5.8	21
117	Selective Inhibition of Phosphodiesterase 7 (PDE7) by BRL50481 in Healthy and Ovalbumin-Sensitized Guinea Pigs. 2012 , 12, 16-23		8
116	Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia. 2012 , 2012, 472897		12
115	Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by <i>Streptococcus pneumoniae</i> by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway. <i>Journal of Biological Chemistry</i> , 2012 , 287, 22799-811	5.4	27
114	Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012 , 302, L56-67	5.8	33
113	Emerging drugs for asthma. 2012 , 17, 219-37		10
112	Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 5833-8	2.9	20

111	Genetic basis for personalized medicine in asthma. 2012 , 6, 223-36		31
110	Modulation of Th1/Th2 cytokine production by selective and nonselective phosphodiesterase inhibitors administered to mice. <i>Pharmacological Reports</i> , 2012 , 64, 179-84	3.9	13
109	Therapeutic options for severe asthma. 2012 , 8, 589-97		26
108	Pharmacological explanation for the medicinal use of <i>Juniperus excelsa</i> in hyperactive gastrointestinal and respiratory disorders. 2012 , 66, 292-301		23
107	Roflumilast inhibits the release of chemokines and TNF- α from human lung macrophages stimulated with lipopolysaccharide. <i>British Journal of Pharmacology</i> , 2012 , 165, 1877-1890	8.6	47
106	Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 1644-58	3.4	36
105	Dual β -adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 1523-6	2.9	17
104	Designing, synthesis, and characterization of some novel coumarin derivatives as probable anticancer drugs. <i>Medicinal Chemistry Research</i> , 2013 , 22, 4146-4157	2.2	13
103	Anti-inflammatory treatment of meconium aspiration syndrome: benefits and risks. <i>Respiratory Physiology and Neurobiology</i> , 2013 , 187, 52-7	2.8	7
102	Immunological aspects of phosphodiesterase inhibition in the respiratory system. <i>Respiratory Physiology and Neurobiology</i> , 2013 , 187, 11-7	2.8	19
101	Synthesis of PDE IV inhibitors. First asymmetric synthesis of two of GlaxoSmithKline's highly potent Rolipram analogues. <i>Organic and Biomolecular Chemistry</i> , 2013 , 11, 8082-91	3.9	13
100	Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and their ratios between high- and low-affinity rolipram binding. <i>Journal of Pharmaceutical Sciences</i> , 2013 , 102, 2120-7	3.9	6
99	Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 5851-4	3.4	4
98	Pharmacokinetics, biodistribution and toxicology following intravenous and oral administration of DSM-RX78 and EFB-1, two new 2-(2-fluorobenzamido)benzoate-based PDE4 inhibitors, to rats. <i>Journal of Pharmacy and Pharmacology</i> , 2013 , 65, 345-54	4.8	
97	Dimerization of TCTP and its clinical implications for allergy. <i>Biochimie</i> , 2013 , 95, 659-66	4.6	16
96	Effects of selective inhibition of PDE4 and PDE7 on airway reactivity and cough in healthy and ovalbumin-sensitized guinea pigs. <i>Advances in Experimental Medicine and Biology</i> , 2013 , 756, 57-64	3.6	19
95	Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013 , 23, 375-81	2.9	25
94	PGE 2 desensitizes β agonist effect on human lung fibroblast-mediated collagen gel contraction through upregulating PDE4. <i>Mediators of Inflammation</i> , 2013 , 2013, 145197	4.3	1

93	Novel therapies in asthma: leukotriene antagonists, biologic agents, and beyond. <i>American Journal of Therapeutics</i> , 2013 , 20, 79-103	1	18
92	Selective Phosphodiesterase 4B Inhibitors: A Review. <i>Scientia Pharmaceutica</i> , 2014 , 82, 453-81	4.3	26
91	Polymorphisms in PDE4D are associated with a risk of COPD in non-emphysematous Koreans. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014 , 11, 652-8	2	9
90	Advances in targeting cyclic nucleotide phosphodiesterases. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 290-314	64.1	488
89	Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014 , 24, 2689-92	2.9	3
88	Discovery of 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as a new series of potent phosphodiesterase 7 inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 9844-54	8.3	14
87	Syntheses of [14C]-labeled 2-(3-chlorophenyl)-3-[3-(3-hydroxy)pyridin-4-yl propoxy]pyridine, a phosphodiesterase 4 inhibitor and its metabolites. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014 , 57, 477-9	1.9	
86	Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?. <i>Drugs</i> , 2014 , 74, 1983-92	12.1	23
85	PDE inhibitors currently in early clinical trials for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1267-75	5.9	27
84	Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. <i>Current Opinion in Pharmacology</i> , 2014 , 16, 89-107	5.1	25
83	Phosphodiesterase 4 inhibitor roflumilast improves the bronchodilative effect of sevoflurane in sensitized airways. <i>Anesthesiology</i> , 2014 , 120, 1152-9	4.3	2
82	The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review. <i>Journal of Inflammation</i> , 2015 , 12, 54	6.7	23
81	Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015 , 25, 649-53	2.9	7
80	CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 559-67	4.7	51
79	CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration—in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 568-78	4.7	34
78	Pyridazinone: an important element of pharmacophore possessing broad spectrum of activity. <i>Medicinal Chemistry Research</i> , 2015 , 24, 3579-3598	2.2	31
77	Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β -Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015 , 52, 634-40	5.7	26
76	Osthol attenuates neutrophilic oxidative stress and hemorrhagic shock-induced lung injury via inhibition of phosphodiesterase 4. <i>Free Radical Biology and Medicine</i> , 2015 , 89, 387-400	7.8	34

75	Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 531-45	11.5	126
74	Heterogeneity of pulmonary endothelial cyclic nucleotide response to <i>Pseudomonas aeruginosa</i> ExoY infection. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015 , 309, L1199-207	5.8	20
73	Pharmacotherapy of critical asthma syndrome: current and emerging therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2015 , 48, 7-30	12.3	11
72	MicroRNA Mediated Chemokine Responses in Human Airway Smooth Muscle Cells. <i>PLoS ONE</i> , 2016 , 11, e0150842	3.7	26
71	JM25-1, a Lidocaine Analog Combining Airway Relaxant and Antiinflammatory Properties: Implications for New Bronchospasm Therapy. <i>Anesthesiology</i> , 2016 , 124, 109-20	4.3	11
70	Dual Inhibition of Ca(+2) Influx and Phosphodiesterase Enzyme Provides Scientific Base for the Medicinal Use of <i>Chrozophora prostrata</i> Dalz. in Respiratory Disorders. <i>Phytotherapy Research</i> , 2016 , 30, 1010-5	6.7	1
69	Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones. <i>Pharmacology & Therapeutics</i> , 2016 , 164, 82-96	13.9	35
68	The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2016 , 11, 733-44	6.2	26
67	Bronchodilator and Anti-Inflammatory Action of Theophylline in a Model of Ovalbumin-Induced Allergic Inflammation. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 935, 53-62	3.6	6
66	Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1133-46	4.1	39
65	Surgical Repair of Mitral Valve Disease in Children: Perioperative Changes in Respiratory Function. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016 , 30, 1286-95	2.1	
64	Direct C C coupling of phthalazine-N-oxide with the carboranyl anion [An original approach to C-modification of carboranes. <i>Journal of Organometallic Chemistry</i> , 2017 , 830, 93-99	2.3	4
63	SKI3301, a purified herbal extract from <i>Sophora tonkinensis</i> , inhibited airway inflammation and bronchospasm in allergic asthma animal models in vivo. <i>Journal of Ethnopharmacology</i> , 2017 , 206, 298-305	5.5	16
62	6-Hydroxy-5,7-dimethoxy-flavone suppresses the neutrophil respiratory burst via selective PDE4 inhibition to ameliorate acute lung injury. <i>Free Radical Biology and Medicine</i> , 2017 , 106, 379-392	7.8	19
61	Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs. <i>Experimental Lung Research</i> , 2017 , 43, 407-416	2.3	12
60	Two Phase Modulation of [Formula: see text] Entry and Cl/[Formula: see text] Exchanger in Submandibular Glands Cells by Dexmedetomidine. <i>Frontiers in Physiology</i> , 2017 , 8, 86	4.6	6
59	Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005680	4.8	29
58	Evaluation of the colo-protective effects of tadalafil in an experimental model of ulcerative colitis in rats. <i>African Journal of Pharmacy and Pharmacology</i> , 2017 , 11, 385-393	0.5	3

57	Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2018 , 146, 381-394	6.8	23
56	Inhibitors of phosphodiesterases in the treatment of cough. <i>Respiratory Physiology and Neurobiology</i> , 2018 , 257, 107-114	2.8	9
55	Assessment of the Airway Smooth Muscle Relaxant Effect of Drotaverine. <i>Pharmacology</i> , 2018 , 101, 163-169	2.6	9
54	Cigarette smoke up-regulates PDE3 and PDE4 to decrease cAMP in airway cells. <i>British Journal of Pharmacology</i> , 2018 , 175, 2988-3006	8.6	20
53	Phosphodiesterase 4 and 7 inhibitors produce protective effects against high glucose-induced neurotoxicity in PC12 cells via modulation of the oxidative stress, apoptosis and inflammation pathways. <i>Metabolic Brain Disease</i> , 2018 , 33, 1293-1306	3.9	9
52	Natural products as modulators of the cyclic-AMP pathway: evaluation and synthesis of lead compounds. <i>Organic and Biomolecular Chemistry</i> , 2018 , 16, 6372-6390	3.9	14
51	Toll-like receptors and their therapeutic potential in Parkinson's disease and Synucleinopathies. <i>Brain, Behavior, and Immunity</i> , 2019 , 81, 41-51	16.6	37
50	Experimental and investigational phosphodiesterase inhibitors in development for asthma. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 261-266	5.9	5
49	Deducting MicroRNA-Mediated Changes Common in Bronchial Epithelial Cells of Asthma and Chronic Obstructive Pulmonary Disease-A Next-Generation Sequencing-Guided Bioinformatic Approach. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	25
48	Inhibitory effects of sildenafil and tadalafil on inflammation, oxidative stress and nitrosative stress in animal model of bronchial asthma. <i>Pharmacological Reports</i> , 2019 , 71, 517-521	3.9	16
47	Phosphodiesterases as therapeutic targets for respiratory diseases. <i>Pharmacology & Therapeutics</i> , 2019 , 197, 225-242	13.9	48
46	Effects of intravenous phosphodiesterase inhibitors and corticosteroids on severe meconium aspiration syndrome. <i>Journal of the Chinese Medical Association</i> , 2019 , 82, 568-575	2.8	5
45	Vinpocetine regulates levels of circulating TLRs in Parkinson's disease patients. <i>Neurological Sciences</i> , 2019 , 40, 113-120	3.5	6
44	Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies. <i>Respiration</i> , 2020 , 99, 550-565	3.7	7
43	Cigarette smoke exposure alters phosphodiesterases in human structural lung cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020 , 318, L59-L64	5.8	7
42	The phosphodiesterase-4 inhibitor roflumilast impacts <i>Schistosoma mansoni</i> ovipositing in vitro but displays only modest antischistosomal activity in vivo. <i>Experimental Parasitology</i> , 2020 , 208, 107793	2.1	4
41	Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor. <i>Heliyon</i> , 2020 , 6, e04856	3.6	4
40	The immunomodulatory role of PDEs inhibitors in immune cells: therapeutic implication in rheumatoid arthritis. <i>Pharmacological Research</i> , 2020 , 161, 105134	10.2	5

39	Pfaffia glomerata hydroalcoholic extract stimulates penile tissue in adult Swiss mice. <i>Journal of Ethnopharmacology</i> , 2020 , 261, 113182	5	6
38	Imperatorin Alleviates Psoriasiform Dermatitis by Blocking Neutrophil Respiratory Burst, Adhesion, and Chemotaxis Through Selective Phosphodiesterase 4 Inhibition. <i>Antioxidants and Redox Signaling</i> , 2021 , 35, 885-903	8.4	4
37	Lung Macrophage Functional Properties in Chronic Obstructive Pulmonary Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	21
36	Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, F576-F588	4.3	13
35	Simultaneous quantification and pharmacokinetic evaluation of roflumilast and its N-oxide in cynomolgus monkey plasma by LC-MS/MS method. <i>Biomedical Chromatography</i> , 2021 , 35, e4973	1.7	
34	Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors. <i>RSC Medicinal Chemistry</i> , 2021 , 12, 584-592	3.5	1
33	New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 291-302	3	4
32	Early administration of milrinone ameliorates lung and kidney injury during sepsis in juvenile rats. <i>Pediatrics International</i> , 2021 ,	1.2	0
31	Nitration of protein kinase G-1 β modulates cyclic nucleotide crosstalk via phosphodiesterase 3A: Implications for acute lung injury. <i>Journal of Biological Chemistry</i> , 2021 , 297, 100946	5.4	0
30	Drug Discovery and Target Identification against Schistosomiasis: a Reality Check on Progress and Future Prospects. <i>Current Topics in Medicinal Chemistry</i> , 2021 ,	3	1
29	Current Asthma Treatments. <i>SpringerBriefs in Immunology</i> , 2021 , 19-25		0
28	Phosphodiesterase 4D, cAMP specific. <i>The AFCS-nature Molecule Pages</i> ,		10
27	The cytokine network in asthma and chronic obstructive pulmonary disease. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3546-56	15.9	652
26	Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. <i>PLoS ONE</i> , 2011 , 6, e17091	3.7	59
25	Synergistic effect of caffeine and glucocorticoids on expression of surfactant protein B (SP-B) mRNA. <i>PLoS ONE</i> , 2012 , 7, e51575	3.7	18
24	Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors. <i>PLoS ONE</i> , 2016 , 11, e0162895	3.7	4
23	Inhibition of ABCC1 Decreases cAMP Egress and Promotes Human Airway Smooth Muscle Cell Relaxation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021 ,	5.7	1
22	Emerging Nonsteroidal Anti-Inflammatory Therapies Targeting Specific Mechanisms in Asthma and Allergy. 2009 , 465-482		

21	Theophylline and Phosphodiesterase Inhibitors. 2009 , 1505-1516		
20	The Future of COPD. 2011 , 75-90		
19	Phosphodiesterase Inhibitors in Obstructive Lung Disease. 296-310		
18	Novel Anti-Inflammatory Treatments for Asthma and COPD. 154-202		
17	The Future of COPD. 2013 , 77-92		
16	Neutrophils and Their Mediators in Asthma and Allergic Disease. 2009 , 179-193		
15	Treating COPD with PDE 4 inhibitors. <i>International Journal of COPD</i> , 2007 , 2, 517-33	3	18
14	Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. <i>Frontiers in Pharmacology</i> , 2021 , 12, 740803	5.6	5
13	Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo. <i>Cancers</i> , 2021 , 13,	6.6	
12	Ligustrazine Inhibits Lung Phosphodiesterase Activity in a Rat Model of Allergic Asthma.. <i>Computational and Mathematical Methods in Medicine</i> , 2022 , 2022, 1452116	2.8	
11	PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 783050	5.7	2
10	How bad is brazilian ginseng extract for reproductive parameters in mice?. <i>Histology and Histopathology</i> , 2020 , 35, 1135-1149	1.4	
9	Roflumilast (Daliresp [®]) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021 , 38, e2021035	1.1	1
8	Rolipram and pentoxifylline combination ameliorates experimental diabetic neuropathy through inhibition of oxidative stress and inflammatory pathways in the dorsal root ganglion neurons.		0
7	Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF- κ B-NLRP3 Inflammasome Signaling Pathway. 2022 , 200, 561-572		0
6	Circulating MicroRNAs Expression Profile in Lung Inflammation: A Preliminary Study. 2022 , 11, 5446		3
5	Apremilast ameliorates acute respiratory distress syndrome by inhibiting neutrophil-induced oxidative stress. 2022 ,		0
4	The role of lung macrophages in chronic obstructive pulmonary disease. 2022 , 107035		1

- 3 Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. 13, ○
- 2 cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features. **2023**, 34, 101438 ○
- 1 Advances in the development of phosphodiesterase 7 inhibitors. **2023**, 250, 115194 ○